COMPANY
Takeda
FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Design Delivery Lead | IND - Bengaluru | Oct 22, 2026 | Oct 12, 2026 |
| HVAC Design Lead | IND - Bengaluru | Oct 22, 2026 | Oct 12, 2026 |
| Produktionsmitarbeiter sterile Abfüllung Mo-Fr (w/m/d), On Site | Vienna, Austria | Oct 22, 2026 | Oct 12, 2026 |
| Senior Manager, GDO Analytics & Insights | IND - Bengaluru | Oct 22, 2026 | Oct 16, 2026 |
| Manager, GDO Analytics & Insights | IND - Bengaluru | Oct 22, 2026 | Oct 16, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 3 trial (NCT07623161, actual start Sep 10, 2026) (+1 other new trial); 39 clinical-operations roles open. ClinicalTrials.gov NCT07623161 (Sep 10, 2026)
Evidence (2 events)
- Sep 10, 2026 · ClinicalTrials.gov NCT07623161
leadSponsor.name='Takeda'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-10,type:ACTUAL}; studyFirstPostDate=2026-06-03; briefTitle='A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib' - Aug 13, 2026 · ClinicalTrials.gov NCT07403968
leadSponsor.name='Takeda'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-13,type:ACTUAL}; studyFirstPostDate=2026-02-11; briefTitle="A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease"
- Sep 10, 2026 · ClinicalTrials.gov NCT07623161
- Drug approval + hiring FDA novel approval for MIMRYLO (NDA 220605, Aug 28, 2026; +1 other approval); 530 manufacturing/quality or commercial roles open. FDA NDA 220605 (Aug 28, 2026)
Evidence (2 events)
- Aug 28, 2026 · FDA NDA 220605
openFDA drugsfda: application_number=NDA220605; sponsor_name='TAKEDA PHARMS AM'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260828; submission_class_code=TYPE 1; brand_name=['MIMRYLO'] - Aug 5, 2026 · FDA NDA 220860
openFDA drugsfda: application_number=NDA220860; sponsor_name='TAKEDA PHARMS USA'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260805; submission_class_code=TYPE 1; brand_name=['ORZEYFUL']
- Aug 28, 2026 · FDA NDA 220605
Timeline
- Trial start —: A Study of Secondary Immunodeficiencies in Adults With Blood Cancers in Kazakhstan Who Have a Weakened Immune System (K-SIDE Study) source ↗
- Trial start —: A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion source ↗
- Trial start —: A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera source ↗
- Trial start Phase 2: A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant source ↗
- Trial start Phase 3: A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib source ↗
- Trial start —: A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland source ↗
- Trial start Phase 2: A Study of Rusfertide in Japanese Adults With Polycythemia Vera source ↗
- Trial start Phase 2/Phase 3: A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia source ↗
- Trial start —: A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma source ↗
- Trial start Phase 3: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions source ↗
- Trial start Phase 2: A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes source ↗
- Trial start Phase 3: A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) source ↗
- Trial start —: A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico source ↗
- Trial start Phase 1/Phase 2: A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors source ↗
- Trial start Phase 2: A Study of Zasocitinib in Adults With Nonsegmental Vitiligo source ↗
- Trial start Phase 3: A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) source ↗
- Trial start —: A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea source ↗
- Trial start Phase 3: A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy source ↗
- Trial start Phase 2: A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) source ↗
- Trial start Phase 3: A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions source ↗
- Trial start Phase 4: A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting source ↗
- Trial start Phase 3: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines source ↗
- Trial start Phase 3: A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia source ↗
- Trial start —: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium source ↗
- Trial start Phase 3: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections source ↗
Upcoming milestones
- Nov 30, 2026 (ESTIMATED) · Phase 2 · A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) · NCT06952699
- Dec 31, 2026 (ESTIMATED) · · A Study of NINLARO® in Chinese Adults With Multiple Myeloma · NCT05013190
- Dec 31, 2026 (ESTIMATED) · · A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea · NCT06550882
- Feb 17, 2027 (ESTIMATED) · Phase 2 · A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease · NCT06233461
- Mar 1, 2027 (ESTIMATED) · · A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera · NCT07868081
- Apr 14, 2027 (ESTIMATED) · Phase 3 · A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) · NCT06579755
- May 1, 2027 (ESTIMATED) · Phase 4 · A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting · NCT06581328
- May 18, 2027 (ESTIMATED) · Phase 3 · A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines · NCT06671483
Clinical trials (lead sponsor) Showing 50 of 1,024
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07868081 | A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera | Not listed | Not yet recruiting | Dec 1, 2026 | Mar 1, 2027 (estimated) |
| NCT07868107 | A Study of Secondary Immunodeficiencies in Adults With Blood Cancers in Kazakhstan Who Have a Weakened Immune System (K-SIDE Study) | Not listed | Not yet recruiting | Apr 1, 2027 | Sep 30, 2027 (estimated) |
| NCT06405087 | A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) | Phase 3 | Recruiting | Oct 27, 2025 | Aug 12, 2030 (estimated) |
| NCT06952699 | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | Phase 2 | Recruiting | May 6, 2025 | Nov 30, 2026 (estimated) |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Phase 3 | Recruiting | May 6, 2025 | May 1, 2028 (estimated) |
| NCT04809363 | A Study of CDPATH™ to Help Manage and Treat Crohn's Disease | Phase 4 | Completed | Jun 25, 2021 | Aug 27, 2026 (actual) |
| NCT06581328 | A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | Phase 4 | Recruiting | Mar 27, 2025 | May 1, 2027 (estimated) |
| NCT04530123 | Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet | Phase 2 | Completed | Jun 23, 2022 | Dec 9, 2025 (actual) |
| NCT07319845 | A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes | Phase 2 | Recruiting | Apr 22, 2026 | Jun 26, 2028 (estimated) |
| NCT05561647 | A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey) | Not listed | Completed | Aug 1, 2013 | Aug 26, 2026 (actual) |
| NCT07353099 | A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma | Not listed | Recruiting | May 26, 2026 | Apr 1, 2030 (estimated) |
| NCT07648030 | A Study of Rusfertide in Japanese Adults With Polycythemia Vera | Phase 2 | Recruiting | Jul 14, 2026 | Oct 28, 2027 (estimated) |
| NCT05669729 | A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion | Not listed | Not yet recruiting | Jan 31, 2027 | Jun 30, 2027 (estimated) |
| NCT07613359 | A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant | Phase 2 | Not yet recruiting | Oct 15, 2026 | Jan 15, 2029 (estimated) |
| NCT07623161 | A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib | Phase 3 | Recruiting | Sep 10, 2026 | Dec 7, 2029 (estimated) |
| NCT06963827 | A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | Phase 3 | Recruiting | Jul 15, 2025 | Sep 7, 2028 (estimated) |
| NCT05755035 | A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases | Phase 2/Phase 3 | Completed | Oct 24, 2023 | Jan 20, 2026 (actual) |
| NCT07108283 | A Study of Zasocitinib in Adults With Nonsegmental Vitiligo | Phase 2 | Recruiting | Nov 3, 2025 | Oct 12, 2027 (estimated) |
| NCT05886491 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/Phase 2 | Terminated | Jul 11, 2023 | Aug 20, 2025 (actual) |
| NCT06233461 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | Phase 2 | Recruiting | Mar 5, 2024 | Feb 17, 2027 (estimated) |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | Phase 1/Phase 2 | Terminated | Mar 8, 2021 | Jun 17, 2025 (actual) |
| NCT06439342 | A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections | Phase 3 | Completed | Dec 16, 2024 | Jul 22, 2026 (actual) |
| NCT05526391 | A Study of TAK-341 in Treatment of Multiple System Atrophy | Phase 2 | Completed | Nov 16, 2022 | Jul 28, 2025 (actual) |
| NCT04266795 | A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy | Phase 2 | Completed | Oct 13, 2020 | Sep 6, 2022 (actual) |
| NCT07205718 | A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Phase 1/Phase 2 | Recruiting | Nov 19, 2025 | Dec 26, 2028 (estimated) |
| NCT07623174 | A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland | Not listed | Recruiting | Aug 13, 2026 | Mar 31, 2028 (estimated) |
| NCT06579755 | A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) | Phase 3 | Active, not recruiting | Jan 20, 2026 | Apr 14, 2027 (estimated) |
| NCT06095128 | A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | Phase 4 | Recruiting | Jun 12, 2024 | Jul 9, 2027 (estimated) |
| NCT07422480 | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Phase 3 | Recruiting | May 21, 2026 | Apr 30, 2029 (estimated) |
| NCT06722235 | A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | Phase 3 | Recruiting | Feb 27, 2025 | Mar 16, 2028 (estimated) |
| NCT07646678 | A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia | Phase 2/Phase 3 | Recruiting | Jun 11, 2026 | Jun 15, 2031 (estimated) |
| NCT05013190 | A Study of NINLARO® in Chinese Adults With Multiple Myeloma | Not listed | Active, not recruiting | Oct 29, 2021 | Dec 31, 2026 (estimated) |
| NCT06671483 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Phase 3 | Recruiting | Mar 3, 2025 | May 18, 2027 (estimated) |
| NCT04461483 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants | Phase 1 | Completed | Aug 13, 2020 | Nov 14, 2020 (actual) |
| NCT05602818 | A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience | Phase 1 | Completed | Nov 15, 2022 | Jun 29, 2023 (actual) |
| NCT02497235 | A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 | 1 | Completed | 2015-07 | 2015-12 (actual) |
| NCT02201056 | Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935 | Phase 1 | Completed | 2014-07 | 2015-07 (actual) |
| NCT05098054 | A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function | Phase 1 | Completed | Oct 29, 2021 | May 31, 2022 (actual) |
| NCT02539134 | TAK-935 Multiple Rising Dose Study in Healthy Participants | Phase 1 | Completed | 2015-09 | 2016-04 (actual) |
| NCT03166215 | Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies | Phase 1/Phase 2 | Completed | Aug 17, 2017 | Sep 19, 2018 (actual) |
| NCT04992442 | Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants | Phase 1 | Completed | Jul 9, 2020 | Aug 18, 2020 (actual) |
| NCT02906813 | A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants | Phase 1 | Completed | Sep 12, 2016 | Oct 12, 2016 (actual) |
| NCT03650452 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies | 2 | Completed | Aug 8, 2018 | Jun 9, 2020 (actual) |
| NCT07494058 | A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico | Not listed | Terminated | Dec 11, 2025 | Jul 3, 2026 (actual) |
| NCT06677892 | A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium | Not listed | Active, not recruiting | Feb 24, 2025 | Aug 1, 2026 (actual) |
| NCT06550882 | A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea | Not listed | Recruiting | Jul 22, 2025 | Dec 31, 2026 (estimated) |
| NCT05064449 | A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults | Phase 1 | Completed | Oct 14, 2021 | Nov 21, 2021 (actual) |
| NCT05098041 | A Study of Soticlestat and Rifampin in Healthy Adults | Phase 1 | Completed | Nov 22, 2021 | Feb 16, 2022 (actual) |
| NCT03694275 | A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY) | Phase 2 | Completed | Sep 10, 2018 | Jul 13, 2020 (actual) |
| NCT04938427 | A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome | Phase 3 | Completed | Nov 8, 2021 | Jan 25, 2024 (actual) |
Open jobs 1,068
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Pflegefachkraft (w/m/d) mit Punktionstalent - BioLife Plasmazentrum Wien Favoriten | Vienna, Austria | Oct 22, 2026 | Oct 12, 2026 | Mid |
| Design Delivery Lead | IND - Bengaluru | Oct 22, 2026 | Oct 12, 2026 | Senior |
| HVAC Design Lead | IND - Bengaluru | Oct 22, 2026 | Oct 12, 2026 | Senior |
| Produktionsmitarbeiter sterile Abfüllung Mo-Fr (w/m/d), On Site | Vienna, Austria | Oct 22, 2026 | Oct 12, 2026 | Mid |
| Senior Manager, GDO Analytics & Insights | IND - Bengaluru | Oct 22, 2026 | Oct 16, 2026 | Not stated |
| Manager, GDO Analytics & Insights | IND - Bengaluru | Oct 22, 2026 | Oct 16, 2026 | Not stated |
| Associate Director, Site Budgeting and Contracting | IND - Bengaluru - Research and Development | Oct 22, 2026 | Oct 16, 2026 | Not stated |
| Global Payroll & Time Technology Specialist | IND - Bengaluru | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Medical Affairs Intern (Non-FTE) | Madrid, Spain | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Medical Manager Lithuania | Vilnus, Lithuanuia | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Sr. Broad Market Project Manager, Distribution & Multi-channel, Zhengzhou/Xian/Shenyang | 2 locations, including Commercial, CHN Zhengzhou | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Intern, OBU, NIN, Beijing | CHN - Beijing - Commercial | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Intern, OBU, NIN, Hangzhou | CHN - Hangzhou - Commercial | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Associate Director- API Process Science | Zurich, Switzerland | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Assoc Director, API Process Science | Boston, MA | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Inventory Reporting Manager | Lodz, Poland | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| (Sr.)Market Access Manager, Market Access, Hangzhou | CHN - Hangzhou - Commercial | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Entry-Level Plebotomist | USA - WI - Janesville | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Medical Customer Service | USA - WI - Janesville | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Medical Screener | USA - WI - Janesville | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| MCR, OBU, NIN, Tianjin | CHN - Tianjin - Commercial | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Entry Level Plasma Center Technician | Columbus, OH | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Phlebotomist (On the Job Training!) | Pittsburgh, PA | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Plasma Center - EMT-B | Pittsburgh, PA | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Plasma Center AEMT | Pittsburgh, PA | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Plasma Center EMT-I | Pittsburgh, PA | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Plasma Center Licensed Practical Nurse (LPN) | Pittsburgh, PA | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Plasma Center Paramedic – EMT-P | Pittsburgh, PA | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Plasma Center Technician / Phlebotomist | Pittsburgh, PA | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Director, China External Innovation | Shanghai, China | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Associate Director, China External Innovation | Shanghai, China | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Sourcing Manager | IND - Bengaluru | Oct 21, 2026 | Oct 12, 2026 | Mid |
| Sourcing Associate | IND - Bengaluru | Oct 21, 2026 | Oct 12, 2026 | Mid |
| Sourcing Associate | IND - Bengaluru | Oct 21, 2026 | Oct 12, 2026 | Mid |
| Associate Medical Director, Clinical Science, GI2 TAU | Cambridge, MA | Oct 21, 2026 | Oct 12, 2026 | Senior |
| Contract Operations Analyst | MEX - Santa Fe | Oct 21, 2026 | Oct 12, 2026 | Entry |
| R2R Process Coordinator | Lodz, Poland | Oct 21, 2026 | Oct 12, 2026 | Mid |
| Director, Medical Governance Partner | Zurich, Switzerland | Oct 21, 2026 | Oct 12, 2026 | Senior |
| MCR, OBU, ST, Changzhou | CHN - Remote - Changzhou - Commercial | Oct 21, 2026 | Oct 12, 2026 | Not stated |
| ODBĚROVÁ SESTRA/BRATR pro plazma centrum CHOMUTOV - plný i zkrácený úvazek | CZE - Chomutov | Oct 21, 2026 | Oct 12, 2026 | Not stated |
| Produktionsmitarbeiter Equipmentreinigung und Materialvorbereitung (w/m/d) On Site | Vienna, Austria | Oct 21, 2026 | Oct 12, 2026 | Mid |
| Senior Medical Representative - GI | Bangkok, Thailand | Oct 21, 2026 | Oct 12, 2026 | Senior |
| Sr. Project Manager, Manufacturing | Round Lake, IL | Oct 21, 2026 | Oct 12, 2026 | Senior |
| Specialty Business Manager - IBD (Utah) | USA - UT - Virtual | Oct 21, 2026 | Oct 12, 2026 | Mid |
| Senior Scientist, Process Research, Synthetic Molecule Process Development | Boston, MA | Oct 21, 2026 | Oct 13, 2026 | Senior |
| Account Lead Vaccines | Guanajuato, León, Mexico | Oct 21, 2026 | Oct 13, 2026 | Not stated |
| Drug Product Process Scientist - Small Molecules | Boston, MA | Oct 21, 2026 | Oct 16, 2026 | Not stated |
| Legal Operations & Digital Enablement , Senior Manager | Boston, MA | Oct 21, 2026 | Oct 19, 2026 | Not stated |
| QC Analyst II | USA - CA - Thousand Oaks - Rancho Conejo | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Senior Manager, Business Capability Analyst | Boston, MA | Oct 21, 2026 | Oct 22, 2026 | Not stated |
Connect
See your connections at Takeda on LinkedIn (search by name, results not checked)